TITLE

Bromocriptine for Type 2 Diabetes

AUTHOR(S)
Kuritzky, Louis
PUB. DATE
May 2011
SOURCE
Internal Medicine Alert;5/15/2011 Supplement 3, p71
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article presents a research study regarding the effectiveness of bromocriptine in treating type 2 diabetes.
ACCESSION #
62085588

 

Related Articles

  • Bromocriptine for Type 2 Diabetes. Kuritzky, Louis // Neurology Alert;Jun2011 Clinical Brief, p12 

    The article presents a report by R. A. DeFronzon published in the "Diabetes Care" journal that informed that Bromocriptine is a new and novel treatment for type 2 diabetes (DM2).

  • Bromocriptine for Type 2 Diabetes. Kuritzky, Louis // Infectious Disease Alert;Jun2011 Clinical Briefs in Primary, p12 

    The article discusses research by R. A. DeFronzo on the efficiency of bromocriptine for the treatment of type 2 diabetes, published in a 2011 issue of "Diabetes Care."

  • Bromocriptine for Type 2 Diabetes.  // OB/GYN Clinical Alert;Jun2011 Clinical Brief, p12 

    The article provides a discussion about bromocriptine (BRO) as a novel treatment for type 2 diabetes (DM2) in which it will reset the levels of dopaminergic and sympathetic tone within the central nervous system (CNS).

  • Truth is rarely pure. Ragg, Mark // Bulletin with Newsweek;2/7/95, Vol. 116 Issue 5956, p34 

    Reports on the controversy generated by sale of the drug bromocriptine in Australia. Suppressing breastmilk; Sale in Australia by Sandoz under the brand name Parlodel; Side effects; Strokes, heart attacks, seizures and deaths among women taking the drug; Alternatives for condition which is...

  • Correction.  // Formulary;Oct2007, Vol. 42 Issue 10, p600 

    A correction to the article "Quick-release bromocriptine has favorable cardiovascular safety profile" that was published in the August 2007 issue is presented.

  • A COMPARATIVE STUDY OF ANTIDIABETIC EFFECT OF BROMOCRIPTINE AND METFORMIN IN ALLOXAN-INDUCED DIABETIC RATS. Pathak, Anuj Kumar; Sinha, Praveen Kumar; Sharma, Janardan // International Journal of Pharmaceutical Sciences & Research;Sep2013, Vol. 4 Issue 9, p3653 

    Bromocriptine mesylate quick release formulation has recently been approved by FDA for the treatment of diabetes mellitus. Till now it has been mainly known for its use in Parkinsonism and for suppression of lactation. Present study evaluates and compares the antihyperglycemic effect of the...

  • New formulation of bromocriptine for diabetes. Taylor, James R. // Endocrine Today;Apr2011, Vol. 9 Issue 4, p33 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) of quick-release bromocriptine as a new formulation for the treatment of type 2 diabetes.

  • Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes. DEFRONZO, RALPH A. // Diabetes Care;Apr2011, Vol. 34 Issue 4, p789 

    The article examines the benefits and safety of time-release bromocriptine (Cycloset), a sympatholytic dopamine D&sub2; receptor agonist, for the treatment of type 2 diabetes. According to the author, bromocriptine is considered because its effects are mediated through a resetting of...

  • Efficacy and safety of add on therapy of bromocriptine with metformin in Indian patients with type 2 diabetes mellitus: A randomized open labeled phase IV clinical trial. Ghosh, Arijit; Sengupta, Nilanjan; Sahana, Pranab; Giri, Debasis; Sengupta, Parama; Das, Nina // Indian Journal of Pharmacology;Jan/Feb2014, Vol. 46 Issue 1, p24 

    Objective: To compare the effectiveness and safety of add on therapy of bromocriptine with metformin in type 2 diabetes mellitus (DM) patients. Material and Methods: Adult type 2 DM patients fulfilling the inclusion criteria were randomized in three groups. Group A received metformin (1000 mg/...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics